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ABSTRACT: G-Quadruplex DNAs are folded, non-Watson-Crick structures that can form within guanine-
rich DNA sequences such as telomeric repeats. Previous studies have identified a series of trisubstituted
acridine derivatives that are potent and selective ligands for G-quadruplex DNA. These ligands have
been shown previously to inhibit the activity of telomerase, the specialized reverse transcriptase that
regulates telomere length. The RecQ family of DNA helicases, which includes the Bloom’s (BLM) and
Werner’s (WRN) syndrome gene products, are apparently unique among cellular helicases in their ability
to efficiently disrupt G-quadruplex DNA. This property may be relevant to telomere maintenance, since
it is known that the sole budding yeast RecQ helicase, Sgs1p, is required for a telomerase-independent
telomere lengthening pathway reminiscent of the “ALT” pathway in human cells. Here, we show that
trisubstituted acridine ligands are potent inhibitors of the helicase activity of the BLM and WRN proteins
on both G-quadruplex and B-form DNA substrates. Inhibition of helicase activity is associated with both
a reduction in the level of binding of the helicase to G-quadruplex DNA and a reduction in the degree to
which the G-quadruplex DNA can support DNA-dependent ATPase activity. We discuss these results in
the context of the possible utility of trisubstituted acridines as antitumor agents for the disruption of both
telomerase-dependent and telomerase-independent telomere maintenance.
The RecQ family of DNA helicases is highly conserved
in evolution and has representatives in all organisms that
have been analyzed to date (1, 2). In humans, there are five
RecQ family members, defects in three of which give rise
to disorders associated with genomic instability, namely,
Bloom’s syndrome (BS), Werner’s syndrome (WS), and
Rothmund-Thomson syndrome (RTS) (3-5). A variety of
different chromosomal aberrations are present at an elevated
frequency in cells isolated from individuals with these
disorders (6-9). The hallmark of BS cells is hyper-
recombination between both sister chromatids and homolo-
gous chromosomes, while WS cells characteristically show
the occurrence of large chromosomal deletions (10, 11).
Genomic instability has been noted in RTS cells, but precise
details remain unclear (12). Cancer predisposition is also
observed in all three of these disorders, although this is a
particular feature of BS (6, 7). Significantly, BS individuals
succumb to the full range of cancers seen in the normal
population, but they do so several decades earlier in life than
is generally expected. WS is primarily associated with the
early appearance of several features of the normal aging
process, such as cataracts, osteoporosis, and graying and loss
of hair (8). RTS is rather less well defined, but is character-
ized by skin and skeletal abnormalities (9). The BS and WS
gene products, designated BLM and WRN, respectively, have
been purified and characterized in vitro. As predicted from
their sequences, BLM and WRN are DNA-dependent
ATPases and ATP-dependent helicases that translocate along
DNA in the 3′-5′ direction (13-16). In addition, WRN
possesses a 3′-5′ exonuclease function, which is directed
by a portion of the N-terminal domain of the protein that
acts independently of the centrally located helicase domain
(17-20).
Recent data indicate that BLM and WRN are atypical
DNA helicases with respect to their DNA substrate specific-
ity. Neither enzyme is capable of efficiently binding to or
unwinding a blunt-ended DNA duplex, but both can unwind
a similar substrate containing a 12-nucleotide, noncomple-
mentary internal “bubble” or terminal “fork” (21). Moreover,
both enzymes bind to a synthetic X-structure, which is a
model for the Holliday junction recombination intermediate,
even though this structure has four blunt-ended duplex arms
(22, 23). Indeed, both BLM and WRN can efficiently
promote branch migration of Holliday junctions and may,
therefore, directly participate in certain genetic recombination
reactions (22, 23). Previous studies have indicated, however,
that perhaps the best substrate for BLM and WRN is a
guanine-quadruplex, four-stranded DNA molecule (G41
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DNA), with all four strands being held together by Hoogsteen
hydrogen bonds (24, 25). Quadruplexes can form in vitro
by interactions within or between DNA strands in molecules
containing runs of guanine residues. They can exist in a
variety of forms distinguished by strand orientation and
stoichiometry (26).
Although there is no conclusive proof that G4 DNA can
form in vivo, there are a number of loci within the human
genome that contain guanine-rich sequences that readily form
stable G4 DNA structures in vitro. The best characterized
of these guanine-rich motifs are those that can form within
telomeric repeat DNA, the ribosomal DNA gene cluster,
immunoglobulin heavy chain gene switch regions, and the
c-myc gene promoter (26). If it is assumed that G4 DNA
structures form in vivo, even in a transient manner, they have
the potential to influence normal chromosomal processes
such as DNA replication, transcription, and recombination.
The finding that some cellular proteins can interact selec-
tively with G4 DNA implies that the formation of these
structures may be exploited for normal DNA metabolism.
Indeed, certain proteins, such as Saccharomyces cereVisiae
Rap1p and Hop1p, not only bind G4 DNA structures but
also promote their stable assembly (27).
RecQ helicases have connections with telomeric DNA
structures in addition to their apparent preference for utilizing
G4 DNA as a substrate for their helicase function. For
example, WS is characterized at the cellular level not only
by genomic instability but also by an abnormally short life
span in culture (8). Primary fibroblasts from WS individuals
undergo premature replicative senescence compared to nor-
mal controls, although this does not appear to be associated
with any acceleration in the rate of telomere loss (28).
Ectopic expression of telomerase can overcome the premature
senescence in WS cells (28, 29), suggesting that in WS cells
activation of the senescent state nevertheless involves signals
originating from eroding telomeres. The budding yeast homo-
logue of BLM and WRN, encoded by the SGS1 gene (30,
31), also plays a role in telomere maintenance. Recent data
indicate that yeast cells lacking telomerase maintain their
telomeres via two genetically distinct pathways that depend
on genetic recombination functions; both require RAD52, but
RAD50 and RAD51 define separate pathways (32-34). The
RAD50-dependent process, in which Sgs1p has been shown
to act (32, 33), is mechanistically similar to the human
“ALT” (for alternative lengthening of telomeres) pathway
(35), in that telomeres maintained by this process are
generally very long and contain variable amounts of TG1-3
repeat sequence.
The propensity of guanine-rich telomeric repeat DNA to
form quadruplex structures has attracted a great deal of
attention because of the potential for this to be exploited as
an antitumor therapy (36-38). The basis for this hypothesis
is that in 80-85% of tumor cells telomere length is main-
tained, effectively indefinitely, by the enzyme telomerase.
This specialized reverse transcriptase is generally not ex-
pressed in somatic cells. The absence of telomerase leads to
progressive telomere erosion, and eventually to cellular
senescence and chromosomal end-to-end fusions when telo-
meres erode beyond a critical point (39). Telomerase contains
an endogenous RNA component, which hybridizes with the
single-stranded 3′ end template stretch of telomeric DNA
sequence, to which further guanine repeats are then added.
Folding of this single-stranded telomeric region into G-
quadruplex structures is known to halt telomerase-mediated
synthesis (40), presumably because of interference with the
essential DNA-RNA hybridization step during telomere
elongation. It has been shown that several classes of G4 DNA
interacting ligands can also inhibit telomerase, possibly by
promoting the DNA folding process in a chaperone-type
manner (41-51). These compounds are typified by the
disubstituted acridine compound 1 (44, 45) and the tetra-N-
methylpyridylporphyrin (TMPy) 5 (48, 49) (Figure 1), which
are active against the enzyme in the low micromolar range.
Most of these telomerase inhibitors also show general cellular
cytotoxicity at an equivalent level. We have recently devised
(52) a new series of 3,6,9-trisubstituted acridines that has
significant (40-fold) selectivity for binding to G4 DNA
compared to regular B-form duplex DNA, and has ap-
proximately 100-fold greater potency against telomerase than
has the disubstituted acridine 1.
In this study, we have analyzed whether these di- and
trisubstituted acridines have any inhibitory effect on the
ability of the human BLM and WRN helicases to disrupt
G4 DNA structures. A disubstituted acridine 2 that was
previously found to be inactive against telomerase and to
have lower quadruplex affinity (44-46, 52) was also ex-
amined. A previous study has shown that the quadruplex-
binding ligand PIPER (50, 51) can inhibit the unwinding of
G4 DNA by the Sgs1 helicase (53). We show here that the
acridine-based compounds have potent in vitro inhibitory
1 Abbreviations: BLM, Bloom’s syndrome gene; WRN, Werner’s
syndrome gene; ALT, alternative lengthening of telomeres; G4, guanine
quadruplex; DTT, dithiothreitol.
FIGURE 1: Structures of the substituted acridine and porphyrin
compounds used in this study.
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activity against the human BLM and WRN helicases. This
inhibitory effect is not, however, dependent upon G4 DNA,
since we also show that substituted acridines can inhibit
BLM- and WRN-catalyzed unwinding of µ-form DNA
substrates.
MATERIALS AND METHODS
Proteins. Recombinant human BLM protein was overex-
pressed in S. cereVisiae and purified by Ni2+ chelate affinity
chromatography, as described previously (13, 54). His-tagged
recombinant human WRN protein was expressed in Sf9
insect cells, and purified as described by Orren et al. (55).
Escherichia coli UvrD protein was a kind gift of S. Matson
(University of North Carolina, Chapel Hill, NC). T4 poly-
nucleotide kinase was obtained from New England BioLabs.
Protein amounts are indicated in moles of monomer.
DNA-Binding Ligands. The syntheses and characterizations
of the di- and trisubstituted acridine derivative [compounds
1 (Mr ) 568.97), 2 (Mr ) 653.14), 3 (Mr ) 703.14), and 4
(Mr ) 675.09) (Figure 1)] have been described previously
(44-46, 52). All of the compounds were employed as HCl
salts and dissolved in distilled water. The tetra-N-methylpy-
ridylporphyrin, compound 5 (Mr ) 1363), was purchased
from Sigma as the tosylate salt.
DNA Helicase Substrates. G4-TP substrate was prepared
as described by Sun et al. (24). The TP sequence is a
consensus repeat from the murine immunoglobulin Sç2b
switch region. The synthetic, four-way X-junction (HJX12)
was made by annealing four 50-mer oligonucleotides (X12-
1, X12-2, X12-3, and X12-4) as described previously (22).
X12-1 was 5′-32P-labeled using T4 polynucleotide kinase
before annealing with the other three oligonucleotides. Blunt-
ended double-stranded DNA (DS52) was made from oligo-
nucleotides BL3 and BL4 (22). Blunt-ended double-stranded
DNA with a 12-nucleotide bubble at its center (bub12) was
prepared by annealing oligonucleotides X0 (5′-GACGCT-
GCCGAATTCTGGCTTGCTCGGACATCTTTGCCC-
CCACGTTGACCCG-3′) and BU12 (5′-CGGGTCAACG-
TGGGCAAAGCCAATGCGATCGGCCAGAAT-
TCGGCAGCGTC-3′). The forked DNA structure was made
from two 50-mer oligonucleotides (X12-1 and X12-2), as
described previously (22). All DNA substrates were purified
following electrophoresis on 10% polyacrylamide gels.
DNA Helicase Assays. DNA helicase reaction mixtures
(20 íL) contained 20 mM Tris-HCl (pH 7.5), 2 mM MgCl2,
2 mM ATP, 100 íg/mL BSA, 1 mM dithiothreitol (DTT), 1
nM DNA substrate, and the amounts of BLM, WRN, or
UvrD protein and DNA-binding ligand indicated in the figure
legends. Reactions were initiated by the addition of the
appropriate helicase; the mixtures were incubated at 37 °C
for various times, and the reactions were terminated by the
addition of 2 íL of 0.5 M EDTA. The products were resolved
on 10% nondenaturing polyacrylamide gels run at 4 °C, and
radioactive bands were visualized using a PhosphorImager
(Molecular Dynamics) or by autoradiography. All helicase
data are representative of at least three independent experi-
ments.
Electrophoretic Mobility Shift Assays. Proteins and 32P-
end-labeled DNA substrates were incubated at room tem-
perature for 20 min in reaction buffer containing 20 mM
triethanolamine-HCl (pH 7.5), 2 mM MgCl2, 2 mM adenos-
ine 5′-[ç-thio]triphosphate (ATPçS), 100 íg/mL BSA, 1 mM
DTT, 10 nM BLM/WRN protein, and the amounts of DNA-
binding ligand indicated in the figure legends. Protein-DNA
complexes were then fixed by incubation with 0.25%
glutaraldehyde at 37 °C for 10 min, and the products were
resolved on 5% nondenaturing polyacrylamide gels. Free
DNA and DNA-protein complexes were observed by
autoradiography.
ATPase Assays. ATPase activity was determined by the
level of release of 32Pi from [ç-32P]ATP. The reaction mixture
(140 íL) contained 20 mM Tris-HCl (pH 7.5), 2 mM MgCl2,
100 íg/mL BSA, 1 mM DTT, DNA cofactor (either du-
plex oligonucleotide DS52 or TP-G4 DNA; either at 200
nM nucleotides), 0.2 mM ATP, 50 nCi of [ç-32P]ATP
(3000 Ci/mmol), 5 nM BLM/WRN protein, and 2.5 íM
DNA-binding ligand. Reactions were initiated by the addi-
tion of BLM/WRN protein, and reaction mixtures were
incubated at 37 °C for up to 90 min. At the indicated time
points, 20 íL of the reaction mixture was collected and
mixed with 10 íL of 0.5 M EDTA to stop the reaction. One
microliter of each reaction mixture was spotted onto
CEL300PEI/UV254 (Polygram) thin-layer chromatography
plates, which were rinsed in 100% methanol before separa-
tion of 32Pi from [ç-32P]ATP in buffer containing 0.8 M LiCl
and 0.8 M acetic acid. The products were visualized using a
PhosphorImager or by autoradiography, and the level of
release of 32Pi was calculated by the formula % hydrolysis
) 100P(P + S), where P is the amount of product (32Pi)
and S is the amount of substrate, after quantificaton using
ImageQuant software (Molecular Dynamics). All ATPase
data are representative of at least three independent experi-
ments.
RESULTS
To analyze whether the di- and trisubstituted acridine
derivatives (Figure 1) could influence the unwinding of G4
DNA catalyzed by BLM or WRN, we generated and charac-
terized, using an established method (24), a G4 DNA mole-
cule representing the immunoglobulin heavy chain switch
region (TP-G4). We have shown previously that the BLM
and WRN helicases efficiently unwind TP-G4 and other G4
DNA structures in an ATP-dependent manner (21, 24).
Initial experiments showed that, at a fixed concentration
of 2 í», compounds 3 and 4 were capable of near-complete
inhibition of both BLM- and WRN-mediated unwinding of
TP-G4 DNA. Accordingly, we analyzed in more detail the
relative potency of compounds 1-4 as inhibitors of helicase-
mediated disruption of TP-G4 DNA. Data obtained using a
broad range of inhibitor concentrations (0-100 íM) showed
that compounds 3 and 4 were significantly more potent than
1 and 2 at inhibiting BLM-catalyzed unwinding of TP-G4
DNA (data not shown). To extend this analysis and to
determine IC50 values for each compound, additional un-
winding reactions including BLM or WRN protein were
performed using a narrower range of concentrations for each
compound. These data indicate that compounds 3 and 4 were
15-30-fold more potent as BLM inhibitors than compounds
1 and 2 (Figure 2 and Table 1). The porphyrin molecule 5
also produced significant inhibition of BLM with an IC50
value that was slightly higher than that of 3 and 4 (Figure 2
and Table 1). Identical analyses were conducted substituting
WRN for BLM, with similar results. Compounds 3-5 were
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significantly more potent as WRN inhibitors than 1 and 2
(Figure 3). Moreover, WRN was consistently more sensitive
to inhibition by these G4-interacting ligands than BLM
(Table 1).
The data presented thus far indicate that the di- and
trisubstituted acridine derivatives are capable of inhibiting
the ability of BLM and WRN to unwind G4 DNA. To
analyze the specificity of this inhibitory effect, we studied
whether these acridines could also inhibit BLM- and/or
WRN-catalyzed unwinding of two non-G4-containing DNA
substrates. We have shown previously that both BLM and
WRN efficiently disrupt a synthetic X-junction, which
mimics a Holliday junction recombination intermediate, and
a blunt-ended duplex oligonucleotide substrate containing a
centrally located, 12-nucleotide noncomplementary region
(a so-called bubble substrate) (21-23). In this section of the
study, compound 3 was used as a representative potent
inhibitor of BLM and WRN. The data in Figure 4 indicate
that compound 3 inhibited the ability of both BLM and WRN
to unwind the synthetic X-junction and the bubble substrate.
Moreover, this inhibitory effect was seen at ligand concen-
trations comparable to those required to inhibit unwinding
of TP-G4 DNA by BLM and WRN (compare data in Figures
2 and 3 with those in Figure 4).
Next, we analyzed in more detail two aspects of the
specificity of inhibition of BLM and WRN by substituted
acridines. Because the analyses presented in Figures 2-4
compared G4 DNA and “alternate” DNA molecules such as
the synthetic X-structure, we analyzed whether compound
3 could inhibit BLM- and WRN-mediated unwinding of a
more conventional µ-form DNA molecule. For this, we used
FIGURE 2: Determination of IC50 values for inhibition of BLM-catalyzed unwinding of TP-G4 DNA by G4 DNA-binding ligands. Panels
A-D show autoradiograms of 10% polyacrylamide gels. All lanes, except the controls, contained 3 n» µL», as indicated by the gray bar
above the lanes. These lanes also included increasing concentrations of ligands (from 0 to 16 í») from right to left, as indicated above the
lanes in black with the concentration of ligand in micromolar above. Note that the concentrations of ligand in panels A and B are higher
that those in panels C and D. The control lanes contained no BLM and no ligand (-), to show the position of the G4 DNA, or no ligand
(4) to show the position of the ssDNA product of the BLM action. The positions of the gel origin, G4 DNA substrate, and ssDNA product
are indicated on the right in each case. Panels A-D contained a different ligand in each: (A) compound 1, (B) compound 2, (C) compound
3, and (D) compound 4. Panel E shows quantification of the data from panels A-D. Values represent the % control helicase activity (as
represented by the 0 íM ligand concentration lane). The primary data for compound 5 are not shown.
Table 1: IC50 Values for Inhibition of BLM- and WRN-Mediated
Unwinding of the TP-G4 Substrate by G-Quadruplex Interacting
Ligands
IC50 (íM) IC50 (íM)
ligand BLM WRN ligand BLM WRN
compound 1 6.51 1.38 compound 4 0.25 0.08
compound 2 7.20 1.10 compound 5 0.78 0.33
compound 3 0.40 0.11
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a forked DNA molecule, which is used extensively as a
substrate for DNA helicases. The data in Figure 5 and Table
2 show that compound 3 potently inhibited the unwinding
of the forked DNA catalyzed by either BLM (Figure 5A) or
WRN (Figure 5B). Next, we assessed whether the substituted
acridines were acting a general DNA helicase inhibitors by
studying the ability of compound 3 to block unwinding of
the forked DNA catalyzed by a helicase that is not a member
of the RecQ family. For this, we used E. coli UvrD protein.
We found that while UvrD catalyzed robust unwinding of
the forked substrate, compound 3, even at a concentration
of 10 í», was unable to inhibit this unwinding activity. We
conclude from this section of the study that substituted
acridines inhibit the helicase activity of BLM and WRN,
but not of the non-RecQ family helicase UvrD. Further, we
conclude that these compounds are not specific in their
inhibition of BLM and WRN in reactions that included G4
DNA, because they show a similar ability to inhibit the
unwinding of conventional µ-form DNA molecules.
Next, we analyzed two aspects of the mechanism by which
acridines could be exerting an inhibitory effect on the helicase
activities of BLM and WRN, namely, whether these ligands
could inhibit the binding of the helicases to DNA and/or
inhibit their DNA-dependent ATPase activities. First, we
used electrophoretic mobility shift assays to assess whether
the inhibitory effect of the acridines was accompanied by a
reduction in the extent to which BLM and/or WRN form a
complex with the TP-G4 DNA substrate. For this section of
the study, compound 3 was again used as a representative
potent acridine compound, and was compared directly with
porphyrin 5. In the absence of ligand, BLM and WRN caused
retardation of the G4 substrate, producing two or three
protein-DNA complexes that migrated a short distance into
the gel (which were more pronounced for BLM than for
WRN), as well as material that failed to migrate out of the
wells (Figure 6). Addition of increasing concentrations of
either compound 3 or porphyrin 5 had two effects. First, in
the case of BLM, the intensity of the major BLM-G4 DNA
complex declined in a ligand concentration-dependent man-
ner. Second, and more significantly, the intensity of the band
representing free G4 DNA increased correspondingly. For
the reactions that included BLM and compound 3, there was
an apparently reciprocal effect on the level of BLM-G4
DNA and free G4 DNA complexes. The results for com-
pound 5 were less clear-cut, in that the amount of some
BLM-G4 complexes declined, in line with the appearance
of free G4 DNA, but the level of one protein-DNA complex
actually increased at higher compound concentrations. In
experiments that included WRN, the ligands had the effect
both of reducing the level of WRN-G4 DNA complexes
FIGURE 3: Determination of IC50 values for inhibition of WRN-catalyzed unwinding of TP-G4 DNA by G4 DNA-binding ligands. The
processing of data and labeling of panels were as described in the legend of Figure 2. Note that the concentrations of ligand in panels A
and B are higher than those in panels C and D. The primary data for compound 5 are not shown.
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and of causing disruption of the large complex that could
not normally migrate from the gel wells (Figure 6), resulting
in a corresponding increase in the level of free G4 DNA.
Hence, we conclude that compounds 3 and 5 are capable of
causing a reduction in the level of binding of BLM and WRN
to G4 DNA.
We subsequently analyzed whether the acridine 3 could
influence the level of DNA-dependent ATPase activity
exhibited by BLM. Although BLM has no detectable activity
as a helicase against fully duplex DNA (21), we have shown
previously that double-stranded oligonucleotide cofactors are
as efficient as single-stranded cofactors at stimulating the
ATPase activity of BLM (13). Therefore, we compared the
ability of duplex DNA and TP-G4 DNA to support ATPase
activity in the presence and absence of compound 3. The
data in Figure 7 show that compound 3 had no effect on the
ATPase activity of BLM in the presence of a double-stranded
DNA cofactor, but caused a small, but significant, inhibition
of ATPase activity in reactions that included TP-G4 DNA.
These data are consistent with the known selectivity of
compound 3 for binding G4 DNAs compared to B-form
duplex DNA substrates (13).
DISCUSSION
We have shown that di- and trisubstituted acridine deriva-
tives are inhibitors of the unwinding activity Bloom’s and
Werner’s syndrome gene products on a G4 DNA substrate.
This is consistent with their known ability to bind to G4
DNA. Their ranking order of inhibitory potency is consistent
with previous measurements of the level of binding to the
human intramolecular quadruplex formed from a telomeric
22-mer DNA. The two trisubstituted compounds have
markedly superior potency compared to the disubstituted ones
FIGURE 4: Effect of G4 DNA-binding ligands on the helicase activity of BLM and WRN using a synthetic X-junction substrate [HJx12
(A)] or a bubble substrate [Bubble-12 (B)]. Where indicated by the gray bar above the gels, reaction mixtures contained 3 nM BLM or
WRN (as indicated above the labeling). Where indicated in black with concentrations (in micromolar) above the gels, reaction mixtures
also contained ligand. The centrally located control lanes contained either no helicase and no ligand (-) or no helicase and 10 í» ligand
(black square numbered 10 above). In panel A (top gel), the positions of the four-way HJx12 substrate and the three products of unwinding
(three-way junction, two-way junction, and ssDNA) are indicated on the right. In panel B (bottom gel), the positions of the bubble substrate
and ssDNA product are indicated on the right.
FIGURE 5: Effect of compound 3 on the unwinding of a forked
DNA substrate by BLM (A), WRN (B), or UvrD (C). Where
indicated by the gray bar above the gels, reaction mixtures contained
4 nM BLM, WRN, or UvrD. Where indicated in black with
concentrations (in micromolar) above the gels, reaction mixtures
also contained compound 3. The control lanes contained helicase
but no ligand (gray bar), no helicase and no ligand (-), or a sample
of DNA heated to 95 °C for 3 min (4) to reveal the position of
ssDNA. The positions of the forked DNA substrate and the ssDNA
product are indicated on the right.
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(44, 45, 52). Inhibition of helicase function by the acridines
was accompanied by a reduction in the level of binding of
BLM and/or WRN proteins to a G4 DNA structure, and by
an inhibition of DNA-stimulated ATPase activity. Perhaps
more surprisingly, the trisubstituted ligands also inhibited
BLM- and WRN-catalyzed unwinding of three non-G4 DNA
substrates. Despite the fact that two of these non-G4 sub-
strates, the four-way Holliday-type junction and the bubble,
are atypical in that they contain complex DNA structural
features and are blunt-ended, compound 3 also inhibited
BLM- and WRN-catalyzed unwinding of a standard µ-form
DNA helicase substrate, the forked partial duplex. This
suggests that these compounds may have selectivity for DNA
structures with a variety of nonduplex features, not just
quadruplexes.
Sgs1p, the budding yeast homologue of BLM and WRN,
plays a role in a recombination-dependent telomere main-
tenance pathway that is revealed in telomerase-deficient yeast
cells (32-34). This RAD50- and RAD52-dependent pathway
is at least superficially similar to the ALT pathway for
telomere maintenance in immortalized human cells lacking
telomerase, in that it mediates telomere length maintenance
through the addition of terminal TG1-3 repeat units. The
precise mechanism by which these TG repeats are added is
not clear at this stage, although one possible mechanism is
through the copying of TG units located on other chromo-
some ends (or extrachromosomally) following the priming
of DNA synthesis from within a D-loop in a process
resembling break-induced replication (see ref 56 for details).
Although it is not yet clear whether any of the human RecQ
helicases plays a role in telomere length maintenance, several
lines of evidence suggest WRN as a possible candidate for
such a role. First, primary WS fibroblasts undergo premature
replicative senescence compared to normal control cells (28).
Second, ectopic expression of telomerase in WS cells leads
to immortalization (28, 29), indicating that telomerase erosion
or telomere length maintenance defects underly this prema-
ture senescence. Third, expression of WRN can partially
eleviate the telomere length maintenance defects of sgs1¢
mutants (34). Fourth, WRN interacts physically and func-
tionally with the Ku70-Ku80 heterodimeric complex found
at telomeres (57, 58). Nevertheless, it is possible that BLM
or any of the other human RecQ family members plays a
role at telomeres distinct from that of WRN. One circum-
stantial piece of evidence to suggest that this might be the
case is that BLM has been shown to be a component of the
specialized PML nuclear bodies that appear to localize to
the sites of telomeric DNA in those cells in which telomeres
are maintained by the ALT pathway (59).
We suggest that trisubstituted acridines have potential as
novel antitumor agents. Most nondividing cells from somatic
FIGURE 6: Electrophoretic mobility shift assay showing the effect of G4 DNA-binding ligands on the ability of BLM and WRN to form
complexes with TP-G4 DNA. Panel A and panel B represent reaction mixtures containing BLM and WRN, respectively, as shown on the
left. The control lanes contained DNA, but no helicase and no ligand (-), or 10 n» helicase and no ligand (gray bar above lane). These
controls reveal the positions of the free G4 DNA and the protein-G4 complexes, respectively. The lane on the extreme right of panel A
contained only DNA and 5 íM compound 3, to indicate that the ligand did not generate a specific retarded product. All other lanes contained
BLM or WRN at 10 nM, together with increasing concentrations (in micromolar) of G4 DNA-binding ligand (either compound 3 or compound
5, as indicated by the black bars above the lanes). The positions of the free G4 DNA, the protein-G4 DNA complexes, and the gel origin
are shown to the right of each panel.
Table 2: IC50 Values for Inhibition of BLM- and WRN-Mediated
Unwinding of Various DNA Substrates by Compound 3
IC50 (íM) IC50 (íM)
ligand BLM WRN ligand BLM WRN
TP-G4 0.40 0.11 bubble 0.25 0.25
X-junction 0.55 0.40 fork 0.45 0.85
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tissues have no requirement for the enzyme telomerase, since
telomeres generally only shorten as a result of a failure to
adequately replicate to the very tip of linear chromosomes.
However, proliferating cells, such as pluripotent stem cells
or neoplastic cells, have a requirement to prevent such
replication-dependent telomere loss. This requirement is
generally fulfilled by telomerase, but approximately 10-
20% of neoplastic cells maintain their telomeres through a
recombination-mediated process termed ALT (35). In ALT
cells, telomeres are of variable length and are often quite
unstable, but nevertheless, such cells are immortal and can
proliferate continuously in culture. Hence, an antitumor
therapy designed to interfere with telomere maintenance may
be ineffective in a minority of ALT tumors (such as certain
osteosarcomas) if it is targeted solely at the telomerase
enzyme itself. We have recently designed (52) ligands 3 and
4 to be selective binders of telomeric quadruplex DNA, and
thus to be potent inhibitors of the telomerase enzyme
complex. We now show here that they are also potent
inhibitors of the unwinding activity of RecQ family helicases,
when using both G4 DNA and regular B-form DNA as
substrates. The X-junction is a model for the Holliday
junction structure and was used because of the putative role
of RecQ helicases in homologous recombination events.
Thus, the inhibition by these ligands could lead to a decrease
in the extent of recombination-directed telomere lengthening.
These agents may have thus the potential to show a broader
spectrum of antitumor activity than had hitherto been
assumed, because of their potential to disrupt both telom-
erase-dependent and the telomerase-independent pathways
for telomere maintenance. Hence, they may be able to inhibit
proliferation of both telomerase-maintained and ALT-
maintained tumors. This would give dual-function quadruplex
and junction-targeted agents such as compounds 3 and 4 an
important clinical advantage over pure active site or template-
directed telomerase inhibitors, especially if most tumors
contain a small clonal population that have ALT character-
istics. We have shown recently that compound 3 has in vivo
activity against an ovarian tumor model, which is telomerase-
positive (60). Cell-based and appropriate in vivo experiments
are currently underway to examine whether compounds 3
and 4 and their analogues have activity in ALT cells and
tumors.
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